SlideShare ist ein Scribd-Unternehmen logo
1 von 8
Plasma Protein Binding of Drugs in
the Elderly
Presented by: Manju Jakhar
M.Pharm (Pharmacology)
Protein binding
Summary
 Binding to plasma proteins can affect the pharmacokinetics and pharmacodynamics of drugs.
 Age is one of many factors which can affect plasma protein binding of drugs.
 Unfortunately. very few generalities can be drawn from the studies of the effect of age
on protein binding. Whether age has an effect on protein binding is dependent not only
on the drug. but also on the manner in which the study is conducted.
 Several studies involve patients with various disease states making assessment of the effect of
age alone on protein binding difficult. Results of different studies on the same drug do not always
agree –in one case finding no change in protein binding with age and in another.
 Binding to plasma proteins is one of many factors affecting the pharmacokinetics and
pharmacodynamics of drugs.
 Since most drug responses are elicited at receptor sites in extravascular tissues, the
concentration of free or unbound drug in plasma is usually considered to be the active
concentration. Drug binding to plasma proteins can also affect the elimination of drugs from the
body (Rowland 1984).
Factors to be Considered in Evaluation
of Studies
1. Subjects
a) Number of Subjects
b) Age Range
c) Sex
d) Health
e) Drug Interactions
2 Protein Binding Methodology
a) Protein Binding Techniques
b) Temperature
c) Concentration of Drug
3 Statistical Analysis of Data
a) Data Presentation
Effect of Age on Protein Binding of
Specific Drugs
1. Disopyramide
 Most studies report no effect of age on plasma protein binding of disopyramide.
 Johnston and Hamer (1982) could not detect a correlation between the percentage bound
and age in 42 subjects ranging in age from 19 to 61 years.
 Bredesen and Kierulf (1984) could not detect a correlation between the binding of
disopyramide or its major metabolite and age in 60 patients (l6 to 89 years) with unspecified
disease states.
2. Lignocaine (Lidocaine)
 For lignocaine, the plasma protein binding increased with age (Davis et al. 1985).
 when the same data were examined by analysis of variance, the percentage free drug was
not significantly different between the 4 age groups in the study « 30 years, 30 to 49 years,
50 to 69 years and> 69 years).
 The binding ratio was correlated with plasma alpha1-acid glycoprotein concentration, but not
with levels of albumin or non-esterified fatty acids. Cusack et al. (1985) reported a significant
increase in the percentage bound and maximum binding capacity for lignocaine in plasma
from elderly patients, but no change in the dissociation constant for plasma protein binding
of the drug.
3. Quinidine
 Protein binding of quinidine does not appear to be related to age.
 The percentage of free drug was not different in 8 elderly subjects (28.2% free,
ages 60 to 69 years) and 14 young subjects (24.6% free,ages 23 to 24 years) [Ochs
et al. 1978].
 In a second study, the percentage bound was not correlated with age in patients
receiving quinidine therapy (Y osselson-Superstine et al. 1982). However, in both
of these studies, protein binding was measured at variable concentrations of
quinidine in plasma. Ochs et a1. (1978) calculated the average percentage free for
each individual over a 30-hour period following administration of a single 180 to
300mg dose of quinidine.
 In the study of Yosselson-Superstine et al. (1982), binding was determined in
plasma samples collected in the morning from patients receiving 800 to 1400mg of
quinidine daily. Total plasma concentrations of quinidine ranged from 2.42 to
11.25 mg/L. Since protein binding of quinidine is concentration dependent, it
might be difficult to detect an effect of age on protein binding when samples from
each subject contain different concentrations of quinidine.
4. Antibacterials
 Very few studies have investigated the effect of age on protein binding of
antibiotics. Drugs which have been studied include: ceftriaxone, penicillin,
sulphadiazine, vancomycin and the 2 constituents of co-trimoxazole
(trimethoprim and sulphamethoxazole)
 The percentage of free ceftriaxone in plasma was increased in elderly
subjects (15.7% free) compared with young subjects (13.6% free) [Luderer
et al. 1984]. The binding of penicillin was similar in subjects under and
over 50 years of age (Bender et al. 1975).
 The latter study, however, involved only 9 subjects, 5 younger than 50
years and 4 older than 50 years. Protein binding of sulphadiazine,
vancomycin, trimethoprim and sulphamethoxazole also remained
relatively constant in the elderly.
Plasma Protein Binding of Drugs in the Elderly

Weitere ähnliche Inhalte

Was ist angesagt?

Compound het filaggrin mutations
Compound het filaggrin mutationsCompound het filaggrin mutations
Compound het filaggrin mutations
PreveenRamamoorthy
 
Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...
Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...
Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...
M. Luisetto Pharm.D.Spec. Pharmacology
 
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
iosrphr_editor
 
Herbal medicines in cardiac patients
Herbal medicines in cardiac patientsHerbal medicines in cardiac patients
Herbal medicines in cardiac patients
U2009
 

Was ist angesagt? (20)

Meta-Analysis of Mobile Phone-based Interventions for Smoking Cessation Trial...
Meta-Analysis of Mobile Phone-based Interventions for Smoking Cessation Trial...Meta-Analysis of Mobile Phone-based Interventions for Smoking Cessation Trial...
Meta-Analysis of Mobile Phone-based Interventions for Smoking Cessation Trial...
 
Compound het filaggrin mutations
Compound het filaggrin mutationsCompound het filaggrin mutations
Compound het filaggrin mutations
 
PERSONALIZED MEDICINE
PERSONALIZED MEDICINEPERSONALIZED MEDICINE
PERSONALIZED MEDICINE
 
Anticholinergic and mirabegron in detrusor overactivity
Anticholinergic and mirabegron in detrusor overactivityAnticholinergic and mirabegron in detrusor overactivity
Anticholinergic and mirabegron in detrusor overactivity
 
2022 02-20-tassid seminar-5 ASA-mesalazine old drug new tricks-dr tsung-chun ...
2022 02-20-tassid seminar-5 ASA-mesalazine old drug new tricks-dr tsung-chun ...2022 02-20-tassid seminar-5 ASA-mesalazine old drug new tricks-dr tsung-chun ...
2022 02-20-tassid seminar-5 ASA-mesalazine old drug new tricks-dr tsung-chun ...
 
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Pentoxifylline Associated with Other Antioxidants (Multimodal Therapy) on Pat...
Pentoxifylline Associated with Other Antioxidants (Multimodal Therapy) on Pat...Pentoxifylline Associated with Other Antioxidants (Multimodal Therapy) on Pat...
Pentoxifylline Associated with Other Antioxidants (Multimodal Therapy) on Pat...
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Carbamazepine induced steven johnson syndrome a case report
Carbamazepine induced steven johnson syndrome a case reportCarbamazepine induced steven johnson syndrome a case report
Carbamazepine induced steven johnson syndrome a case report
 
An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...
An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...
An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...
 
POST brochure
POST brochurePOST brochure
POST brochure
 
A review on esophageal cancer and monitoring the adverse drug reaction of che...
A review on esophageal cancer and monitoring the adverse drug reaction of che...A review on esophageal cancer and monitoring the adverse drug reaction of che...
A review on esophageal cancer and monitoring the adverse drug reaction of che...
 
Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...
Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...
Luisetto m, behzad n a, ghulam r m. relapses and recurrent chronic bacteric p...
 
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
 
Herbal medicines in cardiac patients
Herbal medicines in cardiac patientsHerbal medicines in cardiac patients
Herbal medicines in cardiac patients
 
Abstract THE EFFECT OF PRETREATMENT WITH TOLL-LIKE RECEPTOR 4 ANTAGONIST RESA...
Abstract THE EFFECT OF PRETREATMENT WITH TOLL-LIKE RECEPTOR 4 ANTAGONIST RESA...Abstract THE EFFECT OF PRETREATMENT WITH TOLL-LIKE RECEPTOR 4 ANTAGONIST RESA...
Abstract THE EFFECT OF PRETREATMENT WITH TOLL-LIKE RECEPTOR 4 ANTAGONIST RESA...
 
Introduction to Bayesian theory
Introduction to Bayesian theoryIntroduction to Bayesian theory
Introduction to Bayesian theory
 
Personalized Medicine: A Tailor Made Solution
Personalized Medicine: A Tailor Made SolutionPersonalized Medicine: A Tailor Made Solution
Personalized Medicine: A Tailor Made Solution
 
Molecular iodinedoxorubicin neoadjuvant_treatment_
Molecular iodinedoxorubicin neoadjuvant_treatment_Molecular iodinedoxorubicin neoadjuvant_treatment_
Molecular iodinedoxorubicin neoadjuvant_treatment_
 

Ähnlich wie Plasma Protein Binding of Drugs in the Elderly

BA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdfBA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdf
NoemiBecerraTello
 

Ähnlich wie Plasma Protein Binding of Drugs in the Elderly (20)

Population pharmacokinetics
Population pharmacokineticsPopulation pharmacokinetics
Population pharmacokinetics
 
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
 
Pharmaogenomics
PharmaogenomicsPharmaogenomics
Pharmaogenomics
 
1. Pharmacogenomics.pptx
1. Pharmacogenomics.pptx1. Pharmacogenomics.pptx
1. Pharmacogenomics.pptx
 
Dr. Obumneke Amadi-Onuoha - 15_ fctr
Dr. Obumneke Amadi-Onuoha - 15_ fctrDr. Obumneke Amadi-Onuoha - 15_ fctr
Dr. Obumneke Amadi-Onuoha - 15_ fctr
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS : GERIATRICS
STUDIES IN SUPPORT OF SPECIAL POPULATIONS : GERIATRICSSTUDIES IN SUPPORT OF SPECIAL POPULATIONS : GERIATRICS
STUDIES IN SUPPORT OF SPECIAL POPULATIONS : GERIATRICS
 
Pharmacogenetics of antipsychotic and antidepressent
Pharmacogenetics of antipsychotic and antidepressentPharmacogenetics of antipsychotic and antidepressent
Pharmacogenetics of antipsychotic and antidepressent
 
Drug development process
Drug development processDrug development process
Drug development process
 
Toxicological studies and bioequivalence
Toxicological studies and bioequivalenceToxicological studies and bioequivalence
Toxicological studies and bioequivalence
 
proteomics and system biology
proteomics and system biologyproteomics and system biology
proteomics and system biology
 
Individualization of dosage regime
Individualization of dosage regimeIndividualization of dosage regime
Individualization of dosage regime
 
15
1515
15
 
Core Components of the Metabolic Syndrome in Nonalcohlic Fatty Liver Disease
Core Components of the Metabolic Syndrome in Nonalcohlic Fatty Liver DiseaseCore Components of the Metabolic Syndrome in Nonalcohlic Fatty Liver Disease
Core Components of the Metabolic Syndrome in Nonalcohlic Fatty Liver Disease
 
Clinical Pharmacokinetics
Clinical PharmacokineticsClinical Pharmacokinetics
Clinical Pharmacokinetics
 
Anticholinergic Drugs And Risk Of Dementia Case-Control Study
Anticholinergic Drugs And Risk Of Dementia  Case-Control StudyAnticholinergic Drugs And Risk Of Dementia  Case-Control Study
Anticholinergic Drugs And Risk Of Dementia Case-Control Study
 
Protein-Drug Interaction
Protein-Drug Interaction Protein-Drug Interaction
Protein-Drug Interaction
 
Pharmacogenomic presentation medication saftey 110417 final2
Pharmacogenomic presentation  medication saftey 110417 final2Pharmacogenomic presentation  medication saftey 110417 final2
Pharmacogenomic presentation medication saftey 110417 final2
 
Pharmacogenetics seminar
Pharmacogenetics seminarPharmacogenetics seminar
Pharmacogenetics seminar
 
various approaches to drug discovery
various approaches to drug discoveryvarious approaches to drug discovery
various approaches to drug discovery
 
BA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdfBA_in_drugs_and_factors_which_modified.pdf
BA_in_drugs_and_factors_which_modified.pdf
 

Mehr von ManjuJhakhar (9)

Schedule y.
Schedule y. Schedule y.
Schedule y.
 
Saturation kinetics.
Saturation kinetics.Saturation kinetics.
Saturation kinetics.
 
Respiratory and reproduction pharmacology
Respiratory and reproduction pharmacology Respiratory and reproduction pharmacology
Respiratory and reproduction pharmacology
 
Immunosuppressants drug
Immunosuppressants drugImmunosuppressants drug
Immunosuppressants drug
 
Good laboratory practice
Good laboratory practiceGood laboratory practice
Good laboratory practice
 
Combinatorial chemistry. in drug discovery
Combinatorial chemistry. in drug discoveryCombinatorial chemistry. in drug discovery
Combinatorial chemistry. in drug discovery
 
Clinical trial study team
Clinical trial study teamClinical trial study team
Clinical trial study team
 
Intercellular signalling pathways
Intercellular signalling pathwaysIntercellular signalling pathways
Intercellular signalling pathways
 
Apoptosis regulation by BCL-2
Apoptosis regulation by BCL-2Apoptosis regulation by BCL-2
Apoptosis regulation by BCL-2
 

Kürzlich hochgeladen

1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 

Kürzlich hochgeladen (20)

Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 

Plasma Protein Binding of Drugs in the Elderly

  • 1. Plasma Protein Binding of Drugs in the Elderly Presented by: Manju Jakhar M.Pharm (Pharmacology)
  • 3. Summary  Binding to plasma proteins can affect the pharmacokinetics and pharmacodynamics of drugs.  Age is one of many factors which can affect plasma protein binding of drugs.  Unfortunately. very few generalities can be drawn from the studies of the effect of age on protein binding. Whether age has an effect on protein binding is dependent not only on the drug. but also on the manner in which the study is conducted.  Several studies involve patients with various disease states making assessment of the effect of age alone on protein binding difficult. Results of different studies on the same drug do not always agree –in one case finding no change in protein binding with age and in another.  Binding to plasma proteins is one of many factors affecting the pharmacokinetics and pharmacodynamics of drugs.  Since most drug responses are elicited at receptor sites in extravascular tissues, the concentration of free or unbound drug in plasma is usually considered to be the active concentration. Drug binding to plasma proteins can also affect the elimination of drugs from the body (Rowland 1984).
  • 4. Factors to be Considered in Evaluation of Studies 1. Subjects a) Number of Subjects b) Age Range c) Sex d) Health e) Drug Interactions 2 Protein Binding Methodology a) Protein Binding Techniques b) Temperature c) Concentration of Drug 3 Statistical Analysis of Data a) Data Presentation
  • 5. Effect of Age on Protein Binding of Specific Drugs 1. Disopyramide  Most studies report no effect of age on plasma protein binding of disopyramide.  Johnston and Hamer (1982) could not detect a correlation between the percentage bound and age in 42 subjects ranging in age from 19 to 61 years.  Bredesen and Kierulf (1984) could not detect a correlation between the binding of disopyramide or its major metabolite and age in 60 patients (l6 to 89 years) with unspecified disease states. 2. Lignocaine (Lidocaine)  For lignocaine, the plasma protein binding increased with age (Davis et al. 1985).  when the same data were examined by analysis of variance, the percentage free drug was not significantly different between the 4 age groups in the study « 30 years, 30 to 49 years, 50 to 69 years and> 69 years).  The binding ratio was correlated with plasma alpha1-acid glycoprotein concentration, but not with levels of albumin or non-esterified fatty acids. Cusack et al. (1985) reported a significant increase in the percentage bound and maximum binding capacity for lignocaine in plasma from elderly patients, but no change in the dissociation constant for plasma protein binding of the drug.
  • 6. 3. Quinidine  Protein binding of quinidine does not appear to be related to age.  The percentage of free drug was not different in 8 elderly subjects (28.2% free, ages 60 to 69 years) and 14 young subjects (24.6% free,ages 23 to 24 years) [Ochs et al. 1978].  In a second study, the percentage bound was not correlated with age in patients receiving quinidine therapy (Y osselson-Superstine et al. 1982). However, in both of these studies, protein binding was measured at variable concentrations of quinidine in plasma. Ochs et a1. (1978) calculated the average percentage free for each individual over a 30-hour period following administration of a single 180 to 300mg dose of quinidine.  In the study of Yosselson-Superstine et al. (1982), binding was determined in plasma samples collected in the morning from patients receiving 800 to 1400mg of quinidine daily. Total plasma concentrations of quinidine ranged from 2.42 to 11.25 mg/L. Since protein binding of quinidine is concentration dependent, it might be difficult to detect an effect of age on protein binding when samples from each subject contain different concentrations of quinidine.
  • 7. 4. Antibacterials  Very few studies have investigated the effect of age on protein binding of antibiotics. Drugs which have been studied include: ceftriaxone, penicillin, sulphadiazine, vancomycin and the 2 constituents of co-trimoxazole (trimethoprim and sulphamethoxazole)  The percentage of free ceftriaxone in plasma was increased in elderly subjects (15.7% free) compared with young subjects (13.6% free) [Luderer et al. 1984]. The binding of penicillin was similar in subjects under and over 50 years of age (Bender et al. 1975).  The latter study, however, involved only 9 subjects, 5 younger than 50 years and 4 older than 50 years. Protein binding of sulphadiazine, vancomycin, trimethoprim and sulphamethoxazole also remained relatively constant in the elderly.